It has been 15 years since the advent of the genome-wide association study (GWAS) era.
Here, we review how this experimental design has realized its promise by facilitating an …

Inflammatory bowel disease (IBD), as a global disease, has attracted much research
interest. Constant research has led to a better understanding of the disease condition and …

Background There is a great unmet need for new therapeutics with novel mechanisms of
action for patients with Crohn's disease. The ADVANCE and MOTIVATE studies showed that …

Genome-wide association studies (GWAS) have revealed important biological insights into
complex diseases, which are broadly expected to lead to the identification of new drug …

Ankylosing spondylitis (AS) is a chronic inflammatory disorder of unknown aetiology. Unlike
other systemic autoimmune diseases, in AS, the innate immune system has a dominant role …

Background & Aims Guselkumab, a selective p19 interleukin-23 antagonist, is approved for
the treatment of plaque psoriasis and psoriatic arthritis. This study evaluated the efficacy and …

This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

Abstract Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of
intensive research because of its crucial role in the pathogenesis of different diseases …

Inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease are
chronic, relapsing and remitting disorders of intestinal inflammation with potential systemic …

Crohn's disease (CD) is a chronic relapsing disorder of the gastrointestinal tract and
represents one of the main entities of inflammatory bowel disease (IBD). CD affects …